Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you saying the Pumps & dumps newsletter is lying?? It's ok if one pumps all day but both sides need to be heard!
Nightly recap, August 14, 2014, Pumps&dumps:
The combined efforts of the plethora of newsletters published by Global Oasis, its sister, Sherwood Ventures and GS Media couldn't prevent the afternoon plastering of CJTF shares. Shares reached their high just after noon, after which relentless bid whacking. When the smoke cleared, 486 of the 521 trades closed as overpays* and just shy of 60 grand was collectively lost.
I am not so sure of that in the compounding industry. Paws factors its' receivables at a cost between 25%-35% of gross revenues.
At one time SCRC was factoring at 14% or 16%; they may still be?
In the compounding industry there are significant workmen's compensation claims; some of which take a year or longer to collect.
1% or 1 1/2% is untrue!
Hit show all posts.
The daily numbers are pretty much meaningless. The numbers represent short volume, not short interest. Short volume may be covered in seconds/minutes with no visibility. Per Finra the only true short interest is published twice a month. It can be found on the otcbb website.
www.pumpsanddumps.com
Yes there was a pump. CJTF is being touted by 23 newsletters as of this morning (Pumps and dumps). You know someone or the company is selling.
Let us not forget the so called "consultants."
The Sec filings say they are giving 17.5% of gross billings ($7.4M) to one consultant out of $9.2M Net Revenues. "One individual" out of two has been added to the board ($7.4M consulting expense out of $9.2 Revenues; OH golly gee.
A lot of banter entering day 2 of Pumps and dumps for the 10th time. Get the newbies.
Interesting. I become confused when I read:
During the three months ended March 31, 2014 and 2013, two consultants made up substantially 100% of the Company’s selling and marketing expense. Management believes the loss of these consultants to this organization would have a material impact on the Company’s consolidated financial position, results of operations, and cash flows. For the three months ended March 31, 2014 and 2013, the consultants earned approximately $7,400,000 and $722,000, respectively. Of the 2014 amounts, approximately $3.8 million consisted of stock-based compensation. The amounts payable at March 31, 2014 and December 31, 2013 were $2,415,701 and $1,411,493, respectively. The terms of each contract entitled the consultant to receive an amount ranging from 13% to 17.5% of the gross prescription sales generated. The Company estimates that these two consultants generated almost 100% of the revenue for each period presented. In addition, on March 31, 2014, we added one of these consultants to the Company’s Board of Directors.
Then I read:
As additional compensation, the Company also pays TPS 17.5% of the gross amount of qualified prescriptions billed and shipped by the Company.
At this point I am not sure if TPS 17.5% comes off gross billings; possibly. I KNOW that $7.4M and $722K are expenses against net revenue. And I keep seeing this 17.5% of gross billings.
My question is since "one of these consultants was added to the Company’s Board of Directors;" is that One and the Same Trestles. And, if so, would that not be a conflict of interest to shareholders. Hell, a board member made $7.4M out of $9.2M net revenues.
Anyway, just my thoughts.
"Seems like it in fact was a 4-way merger."
Financially speaking it sure seems that way. The tail is waging the dog.
Well one individual asked what are the "adjustments/fees" to gross billings and was unable to get an answer. This would explain what is right.
However factoring is also stated to be 25% to 35% of gross billings.
The SEC filings. As additional compensation, the Company also pays TPS 17.5% of the gross amount of qualified prescriptions billed and shipped by the Company.
Incorrect; Trestles Commission is calculated based on gross billings BUT is an expense of Net Revenue.
Listed on Pumps and dumps dangerous promotions this morning; for the 10 time by 3 newsletters.
It is also being touted by 67 newsletters; Pumps and dumps. Run.
Maybe they should buy more metal detectors.
It usually takes alot of words when there is really to much to be said.
Look out below.....this turd is about to go belly up.
Look at the weekly chart; pure distribution thruout July/Aug
Pretty funny. I enjoy readings the Pumps and Dumps newsletters every nite. Everybody should be aware of these penny stocks.
It is "standard language" for unprofitable companies with cash flow problems.
Given the indicators described above, in addition to the capital deficiency and negative working capital, there is substantial doubt about the Company’s ability to continue as a going concern.
Basicly, you are correct. The current financial structure does not allow for a net profit. This is why auditors have stated that paws is NOT a going concern.
Best to believe auditors.
Well we know paws issued 23.5M shares after the 10Q filing; primarily for conversions. May be alot of sellers out there.
Net Revenue is real focus of growth and is about 46% of Gross Billings.
Consultants earn between 28% and 38% of NET Revenues. (13%-17.5% of Gross Revenues)
Factoring is between 54% and 76% of Net Revenues. (25%-35% of Gross Revenues)
Not sure how they will ever make a profit under this Financial Structure.
The SEC filings states they are attempting to do so.
My point is that in-house billing does NOT solve the factoring issue; financing solves the problem!
We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution. We factor all of our receivables under a non-recourse agreement. We will need to complete additional financing transactions in order to replace this factoring with in-house billing and collections. Financing transactions, if any, may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if the Company is able to raise the funds required, it is possible that it could incur unexpected costs and expenses, fail to generate sufficient revenue, or experience unexpected cash requirements that would force the Company to seek alternative financing. Further, if the Company issues additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of the Company’s common stock. If additional financing is not available or is not available on acceptable terms, the Company may have to continue factoring its receivables.
The electronic billing to insurance carriers has nothing to do with Factoring.
Factoring is the result of:
During the three months ended March 31, 2014 and 2013, revenues generated from sales of compounding pharmaceutical products primarily to worker’s compensation patients represented 100% of total revenues. The Company revenues are generated from sales of compounding pharmaceutical products primarily to worker’s compensation patients, located primarily throughout Southern California. At times the collection on these receivables can take in excess of one year, during which the Company, at times, attends legal hearings, files liens to securitize claims, negotiates before worker’s compensation administrative judges, resolves liens with stipulations and orders for defendants to pay, and transmits demands to settle liens filed with the adjuster or defense attorneys.
Paws currently needs factoring to support day to day cash needs. The only real answer is conventional financing; as noted in the SEC filing.
Paws is really too top heavy.
It is also unfortunate that 2 consultants take $8.122M right off the top. Not a whole lot left for shareholders when you have $5.3 factoring and selling/marketing expense of $7.38M.
Management admits they need financing in order to stop the factoring.
$5.3M interest expense attributable to AR factoring.
A 1 for 10 RS is already in process according to their June 26, 2014 pr.
Thu, Jun 26, 2014
10:10 AM Tonogold Announces Results of Annual Shareholder Meeting - GlobeNewswire
The Nightly Recap: July 21, 2014 "Pumps and dumps;
Research Driven Investors' pumping of SCRC decimated investors, a result that has become a fact of life for those who insist on throwing away money on RDI "picks". 321 of 356 trades were overpays and $33K was flushed down the toilet and into the sewer that is the pockets of the scammers. Since the June 2013 Pump & Dump campaign, shares have lost 70% of their value, but hey, at least the number of shares outstanding has doubled.
Express Scripts cuts payments for customized drugs
By MATTHEW PERRONE
— Jul. 3, 2014 10:25 AM EDT
You are here
Home » Health » Express Scripts cuts payments for customized drugs
Read more
States experimenting to lower health care costs
Businesses seek cure for health care cost surge
Share
2
inShare
Tumblr
WASHINGTON (AP) — The nation's largest pharmacy benefit manager, Express Scripts, is dramatically scaling back its coverage of compounded medications, saying most of the custom-mixed medicines are ineffective or overpriced.
The company, which manages prescriptions for 90 million Americans, plans to drop coverage for 1,000 drug ingredients commonly found in compounded medications. Express Scripts executives say the move is a cost-saver for employers that will reduce their spending on compounded prescriptions by 95 percent.
"What we are eliminating is, pure and simple, wasteful spending," said Senior Vice President Glen Stettin, in an interview with The Associated Press. "These drugs are being used when there are other things available that are already approved by the FDA and are less expensive."
But the coverage change has prompted a swift pushback from compounding pharmacists, who argue that such cuts deprive patients of crucial medications that are not available as manufactured drugs. A compounding pharmacy industry spokesman said similar efforts to curb coverage are in the works from several insurers and pharmacy benefit providers, including UnitedHealthcare and some Blue Cross Blue Shield plans.
"This is the first time we've seen a systematic approach to substantially, effectively cut compounding coverage, which ultimately is very detrimental to patients," said Jay McEniry, executive director of Patients and Physicians for Rx Access, a group recently launched by compounding pharmacies.
The cuts by Express Scripts will take effect Sept. 15, unless customers specifically ask to continue paying for the compounded drugs. Companies who want to opt out of the cuts must notify Express Scripts by Thursday.
Express Scripts, CVS Caremark and other pharmacy benefit managers are paid by employers to manage pharmacy costs. They do this by negotiating discounts and rebates from drugmakers and wholesalers, and by setting up tiered drug lists that steer patients toward lower-cost drugs, which are often generics.
In recent years pharmacy benefit companies have focused their cost-saving efforts on new specialty drugs like Sovaldi, a hepatitis C treatment from Gilead Sciences that costs about $1,000 per pill. Express Scripts reported earlier this year that specialty drugs accounted for more than a quarter of all U.S. drug spending, even though they total less than 1 percent of prescriptions. Compounded drugs occupy a different niche in the pharmaceutical landscape.
Compounded medicines are custom-mixed by pharmacists to meet the prescribing instructions provided by a doctor. For instance, if a patient is unable to swallow a pill their doctor may order a liquid formulation of the same drug from a compounding pharmacy.
Express Scripts says patients will still be able to get necessary compounded medicines under its plan. Instead, the company's cuts focus on untested topical creams and ointments used to treat pain and other conditions. For example, Express Scripts says some compounding pharmacies will mix five or more drugs into a pain cream even though there's no evidence that the combination is better than a single-ingredient drug. And in many cases that single ingredient is already available as an over-the-counter drug or a conventional prescription.
"Your health benefit is intended to pay for things that have demonstrated efficacy. These are things that wouldn't pass muster," said Express Scripts' Stettin, who heads the company's clinical research division. He estimates less than a half-percent of patients who get prescriptions through the St. Louis-based company will be affected by the coverage changes.
Along with questionable effectiveness, Stettin says prices for many compounding drugs have risen to unjustifiably high levels. Between the first quarter of 2012 and the first quarter of 2014, Express Scripts says its spending on compounded medications increased nearly 370 percent to $131 million. The average cost of a compounded medicine rose more than tenfold in that period: from $90 to $1,100 per prescription. While some of that increase is due to doctors writing more prescriptions, Express Scripts says the bulk is due to inflation of drug ingredient prices by manufacturers.
Over the last two years, Express Scripts has recorded increases of 100 percent or more in the average price of 117 compounding ingredients. Among that group, 13 ingredients have seen price increases of over 1,000 percent.
In a written statement Wednesday, the compounding coalition said that pharmacies do not control drug ingredient prices. The group also noted that pharmacy benefit managers like Express Scripts can set caps on what they are willing to pay for various medications.
"Express Scripts should explain why it has chosen not to set 'maximum allowable pricing' across the board, rather than attempting to shift responsibility to pharmacists and shift costs to its customers," the group said.
Express Scripts Holding Co. is based in St. Louis.
Share
2
inShare
Tumblr
Yep, some hungry sellers.
Scrc on "PUMPS AND DUMPS" for the 7th time; 9 newsletters
Read the 8K; factoring is interest expense! The value of the receivable less the selling price of the receivable is a financing charge.